Clinical Utility of Central and Peripheral Airway Nitric Oxide in Aging Patients with Stable and Acute Exacerbated Chronic Obstructive Pulmonary Disease

Xiaodong Fan1,*, Nian Zhao2,3,*, Zhen Yu1, Haoda Yu1, Bo Yin1, Lifei Zou1, Yinying Zhao1, Xiufen Qian1, Xiaoyan Sai1, Chu Qin1, Congli Fu1, Caixia Hu1, Tingting Di1, Yue Yang1, Yan Wu1, Tao Bian1

1Departments of Pulmonary and Critical Care Medicine, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu, 214023, People's Republic of China; 2Departments of Pulmonary and Critical Care Medicine, The First People's Hospital of Kunshan, Kunshan, Jiangsu, 215300, People's Republic of China; 3The first medical college of Nanjing Medical University, Nanjing, Jiangsu, 211166, People's Republic of China

*These authors contributed equally to this work

Correspondence: Yan Wu; Tao Bian Department of Pulmonary and Critical Care Medicine, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, Jiangsu, 214023, People's Republic of China. Email wyuyangting@163.com; biantao@126.com

Purpose: Exhaled nitric oxide has been used as a marker of airway inflammation. The NO concentration in the central and peripheral airway/alveolar can be measured by a slow and fast exhalation flow rate to evaluate inflammation in different divisions within the respiratory tract. We hypothesized that FeNO200 (exhaled NO at a flow rate of 200mL/s) could be used as an evaluation tool for peripheral airway/alveolar inflammation and corticosteroid therapy in chronic obstructive pulmonary disease (COPD) patients.

Methods: We recruited 171 subjects into the study: 73 healthy controls, 59 stable COPD patients, and 39 acute exacerbations of COPD (AECOPD) patients. Exhaled nitric oxide (FeNO200 (exhaled NO at a flow rate of 50mL/s)), FeNO40 and CaNO (peripheral concentration of NO/alveolar NO) and clinical variables including pulmonary function, COPD Assessment Test (CAT), C-reactive protein concentration (CRP) and circulating eosinophil count were measured among the recruited participants. FeNO200, FeNO40, and CaNO were repeatedly evaluated in 39 AECOPD patients after corticosteroid treatment.

Results: FeNO200 was significantly higher in stable COPD and AECOPD patients than in healthy controls. Nevertheless, CaNO could not differentiate COPD from healthy controls. No correlation was found between circulating eosinophil counts and FEV1 and exhaled nitric oxide (FeNO200, FeNO40, CaNO) in COPD patients. For AECOPD patients, 64% of patients had eosinophil counts >100 cells/µL; 59% of patients had FeNO200 >10 ppb; only 31% of patients had FeNO200 >25 ppb. Among AECOPD patients, the high FeNO200 and FeNO40 groups’ levels were significantly lower than their baseline levels, and significant improvements in CAT were seen in the two groups after corticosteroid treatment. These implied a good corticosteroid response in AECOPD patients with FeNO200 >10 ppb.

Conclusion: FeNO200 is a straightforward and feasible method to evaluate the peripheral NO concentration in COPD. FeNO200 can be a type 2 inflammation biomarker and a useful tool for predicting corticosteroid therapy in COPD.

Keywords: exhaled nitric oxide, chronic obstruction pulmonary disease, corticosteroid, biomarker

Introduction
Chronic obstructive pulmonary disease (COPD) is a complex polyclinic lung disease characterized by an abnormal inflammatory and a progressive condition with declining lung function. Although airway inflammation in COPD is generally considered to be caused by type 1 immune response, type 2 airway inflammation
can also occur in some COPD patients during stable or exacerbation state. Some studies have found that some COPD patients have gene expression of type 2 inflammation in the airway, and these patients have a good response to corticosteroid. In recent years, there have been a large number of studies on the role of type 2 biomarkers in COPD, including eosinophils, IgE and FeNO. Nitric oxide (NO) is biosynthesized from L-arginine and oxygen by the enzyme NO synthase (NOS) endogenously, fractional concentration of exhaled nitric oxide at a flow rate of 50mL/s (FeNO50) is a known marker of airway inflammation. As a noninvasive, convenient and highly reproducible method for assessing airway inflammation, FeNO measurement has been used to evaluate type 2 inflammation of asthma and guide anti-inflammatory treatment. However, the role of FeNO50 in COPD remains controversial.

According to the latest technical standard published by the European Respiratory Society (ERS) in 2017, FeNO50 (usually abbreviated as FeNO, representing the exhaled NO value at the flow rate of 50mL/s) mainly reflects large airway inflammation from bronchi to respiratory bronchioles, but cannot reflect small airway inflammation. COPD is a respiratory disease characterized by chronic inflammation of the small airway. As a marker of peripheral/small airway inflammation, more and more studies began to pay attention to the clinical value of CaNO (concentration of alveolar NO) in COPD patients. Several studies reported that CaNO was increased in COPD patients and was correlated with a single nitrogen washout curve (dN2) and diffusion capacity for carbon monoxide (DLCO). Nonetheless, some researchers found that there was no difference in CaNO between COPD patients and healthy population. In addition, whether CaNO could guide the treatment of corticosteroid in COPD patients needs further study.

The estimation of CaNO requires three exhalations at three different flow rates that follow the conventional linear regression model. The procedure is complex, especially for AECOPD patients, it is challenging to complete. Therefore, it is necessary to have a simpler and more convenient index than CaNO, but it can also reflect peripheral/small airway inflammation. In 2014, Peter J Barnes found that FeNO200 (fractional concentration of exhaled nitric oxide at a flow rate of 200 mL/s) is proportional to CaNO. By measuring the exhaled NO at the flow rates of 50 mL/s and 200 mL/s, the inflammation of central and peripheral airways can be distinguished. Therefore, FeNO200 (fractional concentration of exhaled NO at a flow rate of 200 mL/s) was used as it maximizes the alveolar fraction of eNO in hereditary hemorrhagic telangiectasia, hepatopulmonary syndrome, and liver cirrhosis. However, the role of FeNO200 in patients with COPD has not been studied.

Our prospective study measured pulmonary function parameters and exhaled nitric oxide (FeNO50, FeNO200, and CaNO) in COPD patients with different stages and controls. For AECOPD patients, we compared these parameters before and after corticosteroid treatment. The purpose of this study was to evaluate a change in peripheral small airway/alveolar sites of NO detected by FeNO200 and CaNO in COPD. Besides, whether FeNO200 or CaNO could be used as an evaluation tool for corticosteroids therapy in AECOPD patients was further explored.

**Materials and Methods**

**Study Subjects**

Stable COPD patients and AECOPD patients were diagnosed based on the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 guidelines. Healthy subjects (HS) with normal lung function as controls were included in the study. All participants were restricted to adults 60 years and older. The physician prescribed the therapy of AECOPD. Patients enrolled at the Department of Respiratory Medicine at the Wuxi People’s Hospital from November 2017 to December 2019.

For all participants with a history of asthma or other respiratory diseases were excluded from the study. The main exclusion criteria were treated with systemic corticosteroids or antibiotics 4 weeks before admission. The hospital Ethics Committee approved the study. We fully abide by the guidelines in the Helsinki declaration and written informed consent was obtained from all participants enrolled in the study.

**Study Design**

Lung function, exhaled nitric oxide, the white blood cell count (WBC), and blood C-reactive protein (CRP) concentration were measured among the controls and COPD patients. For AECOPD patients, methylprednisolone 40mg/day, intravenous administration for 1 week was given. Moreover, before discharged from the hospital, lung function and exhaled nitric oxide would be measured again in AECOPD patients.
Exhaled NO Measurement

Exhaled NO was measured using the Nano Coulomb Breath Analyzer (Sunvou-CA2122, Wuxi, China), in line with the American Thoracic Society/European Respiratory Society (ATS/ERS) recommendations. One hour before the test, eating, smoking, drinking, strenuous exercise or pulmonary function test were prohibited.

Ten healthy controls, ten stable COPD patients, and ten AECOPD patients participated in the preliminary clinical trial. They were required to exhale via a mouthpiece at multiple flow rates: 100, 200, 350 mL/s. At each flow rate, the mean value was calculated. FeNO50 was measured at the single flow rate of 50 mL/s. CaNO was estimated with a mathematical approach based on a two-compartment linear model published by Tsoukias et al. However, the success rate of measurement at a flow rate of 350 mL/s was only 60% for AECOPD patients (Table 1).

A simplified estimation method of alveolar nitric oxide was developed to improve the success rate of measurement. Subjects were informed about inhaling NO-free air and exhaling via a mouthpiece at two constant flow rates: 50, 200 mL/s. FeNO50 and FeNO200 were recorded. CaNO was calculated based on the linear model published by ERS:

\[
\text{FeNO} = \text{CaNO} + \text{JawNO/VE}
\]

FeNO (fractional concentration of exhaled NO) is recorded in ppb (1 ppb = 1x10-9 mol/L). The exhalation flow rate is given as a subscript in mL/s. A flow rate of 50 mL/s is written FeNO50 and a low rate of 200 mL/s is written FeNO200. FeNO is a flow rate dependent index. The smaller the flow rate is, the higher the value is, the better it can reflect NO in a large airway; the higher the flow rate, the smaller the value, the better it can reflect NO in a small airway. JawNO, the total flux of NO in the conducting airway compartment (nl/s), is not affected by the flow rate and only reflects the inflammation of the central/large airway. CaNO, the concentration of alveolar NO, is not affected by the flow rate and only reflects the inflammation of peripheral/small airway.

### Statistical Analysis

SPSS software version 22.0 was used to process data. All continuous variables were checked for normal distribution by Kolmogorov–Smirnov normality test. Normally distributed variables are expressed as mean ± standard deviation, and skewed variables are expressed as the median (interquartile range, IQR). The significance of the difference between the two groups was assessed with a two-tailed Mann–Whitney test (t-test). The differences between multiple groups were evaluated with the nonparametric Kruskal–Wallis test (ANOVA) with Dunn post-test. The chi-square test was used to compare categorical variables between the two groups. Statistical significance was considered to exist when P<0.05.

### Results

**Subject Characteristics**

A total of 98 COPD patients (59 stable COPD patients, 39 AECOPD patients) and 73 healthy controls were enrolled in this study. The characteristics of the study patients are shown in Table 2. There were no statistical differences in terms of age, blood eosinophil percentage, and eosinophil counts. Elevated CRP concentration was seen in COPD patients. Pulmonary function parameters were significantly higher in healthy controls than in COPD patients. In the stable COPD and AECOPD patients, lung function parameters and maintenance therapy were similar. There was no significant difference in the distribution of disease severity between the COPD and AECOPD patients.

### Increased Exhaled Nitric Oxide in Different Stages of COPD

FeNO200 increased in patients with stable COPD [median: 11.0 ppb, IQR: (9.0, 15.0) ppb; P<0.05] and AECOPD patients [median: 11.0 ppb, IQR: (10.0, 14.0) ppb; P<0.05] compared with healthy controls [median: 9.0 ppb, IQR: (6.0, 11.0) ppb]. FeNO50 increased in patients with stable COPD [median: 22.0 ppb, IQR: (17.0, 30.0) ppb; P<0.05] and exacerbated COPD patients [median: 21.0 ppb, IQR: (18.0, 28.0) ppb; P<0.05] compared with healthy controls [median: 20.0 ppb, IQR: (15.0, 25.0) ppb]. However, there was no significant difference in FeNO50 and FeNO200 between stable and exacerbated COPD patients. CaNO demonstrated no significant difference among control subjects [median: 4.4 ppb, IQR: (1.5, 6.7) ppb], stable [median: 5.9 ppb, IQR: (3.5, 8.2) ppb] and exacerbated COPD patients [median: 5.4 ppb, IQR: (2.6, 8.5) ppb] (Figure 1).

### Table 1 The Success Rate of Exhaled Nitric Oxide Measurement at Different Expiratory Flow Rates

| Exhalation Flow Rates, mL/s | 50  | 100 | 200 | 350 |
|-----------------------------|-----|-----|-----|-----|
| Control                     | 100 | 100 | 100 | 90  |
| Stable COPD                 | 100 | 100 | 90  | 70  |
| AECOPD                      | 100 | 100 | 90  | 60  |
There was a positive correlation between FeNO$_{50}$ and CRP ($r=0.384$, $p<0.05$) in stable COPD patients. FeNO$_{200}$ was associated with CRP ($r=0.335$, $p<0.05$) as well. CaNO did not correlate with CRP ($p>0.05$). Forty-seven percent stable COPD patients and 64% AECOPD patients with blood eosinophil counts $\geq 100$cells/ul. No correlation was found between exhaled nitric oxide (FeNO$_{50}$, FeNO$_{200}$, CaNO) and eosinophils ($p>0.05$). In AECOPD patients, there was no correlation between exhaled nitric oxide and eosinophils and CRP ($p>0.05$).

### Effect of Corticosteroids on Exhaled Nitric Oxide in AECOPD Patients

Exhaled NO was repeatedly measured in 39 patients with AECOPD before discharge from the hospital following adequate corticosteroid treatment. During hospitalization, all patients were treated continuously with systemic corticosteroids. There were significant improvements in FeNO$_{50}$, lung function (FEV 1%, PEF, FEF25, FEF50, FEF75) (Table 3).

#### FeNO$_{200} > 10$ppb Predicted a Good Corticosteroid Response in AECOPD

We grouped all patients according to the cut-off point of FeNO$_{50}$, FeNO$_{200}$ and CaNO. According to the clinical guideline published by ATS in 2011, FeNO$_{50}$ values greater than 25ppb indicate eosinophilic inflammation and the likelihood of corticosteroid responsiveness. No guidelines have published cut-off points for FeNO$_{200}$ and CaNO. Based on the literature, the normal values of FeNO$_{200}$ and CaNO in healthy people do not exceed 7.4 ppb and 4.7 ppb, so we use 10ppb and 5ppb as the cut-off point. 20,25,26
There were 11 patients with initial FeNO$_{50}$ > 25 ppb, FeNO$_{50}$ decreased significantly from 51.7±22.7 ppb to 30.3±9.0 ppb (p<0.05) after a week of corticosteroid treatment (Figure 2A). For 28 patients with initial FeNO$_{50}$ ≤ 25 ppb, FeNO$_{50}$ did not change significantly (19.0±3.2 vs 20.0±9.3 ppb; p=0.764) (Figure 2B). There were 23 patients with initial FeNO$_{200}$ > 10 ppb, FeNO$_{200}$ decreased from 16.1±7.8 to 12.2±5.2 after treatment (p<0.05) (Figure 2C). And for 16 patients with initial FeNO$_{200}$ ≤ 10 ppb, there was no significant change after treatment (8.7±1.4 vs 10.3±4.3 ppb; p=0.112) (Figure 2D). There were 18 patients with initial CaNO >5 ppb and 21 patients ≤5 ppb, and no significant change was found in neither group (10.3±5.9 vs 7.4±5.0 ppb, p=0.181; 2.6±1.5 vs 4.5±5.7 ppb, p=0.148; Figure 2E and F).

The patients in the high FeNO$_{50}$ group (FeNO$_{50}$ > 25 ppb) had greater improvement in FeNO$_{50}$ and CAT than the low FeNO$_{50}$ group (FeNO$_{50}$ ≤ 25 ppb) (Table 4). Similar results were found between the high FeNO$_{200}$ group (FeNO$_{200}$ > 10 ppb) and low FeNO$_{200}$ group (FeNO$_{200}$ ≤ 10 ppb) (Table 5). No improvement was observed in both high and low CaNO groups (Table 6).

**No Relationship Between COPD Severity and Exhaled Nitric Oxide**

According to the GOLD criteria, four patients were categorized as GOLD stage 1 (FEV1% pred≥80%), 32 as GOLD stage 2 (80% > FEV1% pred ≥50%), 41 as GOLD stage 3 (50% > FEV1% pred ≥30%) and 21 as stage 4 (FEV1% pred <30%).

The increase of CaNO from GOLD1-2 to GOLD3, GOLD 3 to GOLD 4 was insignificant, but there was a significant increase from GOLD 1-2 to GOLD 4 (Figure 3C). And no difference was found between different GOLD stages in FeNO$_{50}$ and FeNO$_{200}$ (Figure 3A and B).

No correlations were found between FeNO$_{50}$, FeNO$_{200}$, CaNO and FEV1 (p>0.05).

**Table 3** Changes in Exhaled NO and Pulmonary Function in AECOPD Patients After Treatment

|            | Before       | After        | Difference (After-Before) | p value |
|------------|--------------|--------------|---------------------------|---------|
| FeNO$_{50}$| 22.0 (18.0,28.0) | 22.7±9.5     | -3.0 (-10.0,3.0) | 0.037   |
| FeNO$_{200}$| 11.0 (10.0,14.0) | 10.0 (8.0,14.0) | 0.0 (-5.0,2.0) | 0.118   |
| CaNO       | 5.4 (2.7,8.5) | 4.6 (2.5,6.8) | -0.2 (-2.6,2.3) | 0.796   |
| CAT        | 18.00 (15.00,32.00) | 19.00 (11.00,26.00) | -3.00 (-6.00,1.00) | 0.000    |
| FEV1       | 0.90 (0.74,1.46) | 1.07 (0.91,0.59) | 0.12 (-0.04,0.25) | 0.000    |
| FEV1/FVC   | 48.9±11.5 | 52.1±14.3 | 0.52 (-2.2,5.0) | 0.048   |
| FEV1%      | 39.6 (30.15,4.1) | 49.7±15.2 | 4.3 (-2.7,9.8) | 0.003   |
| PEF        | 2.9 (2.0,3.9) | 3.7 (2.6,4.8) | 0.35±1.43 | 0.013   |
| FEF25      | 0.83 (0.58,1.78) | 1.47 (0.72,2.60) | 0.13 (-0.10,0.65) | 0.000    |
| FEF50      | 0.42 (0.28,0.76) | 0.58 (0.37,1.11) | 0.06 (-0.05,0.26) | 0.006    |
| FEF75      | 0.19 (0.15,0.29) | 0.24 (0.16,0.34) | 0.03±0.16 | 0.039    |

**Notes:** Data are presented as mean±standard deviation or median (interquartile range); Kruskal–Wallis test for all other variables.

**Figure 1** Exhaled nitric oxide in healthy controls, stable and exacerbated COPD patients. FeNO$_{50}$ increased in stable and exacerbated COPD patients (A). FeNO$_{200}$ increased in stable and exacerbated COPD patients (B). There was no significant difference of CaNO in healthy controls, stable and exacerbated COPD patients (C).
Discussion

Invasive sampling, such as lung biopsy or bronchoalveolar lavage (BAL), poses a risk to COPD patients, making it difficult to assess small airway and alveoli inflammation directly. Exhaled NO has been used as a noninvasive biomarker of airway inflammation since it was discovered. According to ERS guideline, FENO\textsubscript{50} = CANO + JawNO/50 at the flow rate of 50mL/s and FENO\textsubscript{200} = CANO + JawNO/200 at the flow rate of 200mL/s. JawNO is the NO flux in the large airway, which reflects the NO production and inflammation in the large airway, and is not affected by the flow rate; similarly, CANO is the alveolar NO concentration, which completely reflects the small airway inflammation and is not affected by the flow rate. Therefore, FENO\textsubscript{50} reflects more JawNO, that is, NO concentration in large airway, while FENO\textsubscript{200} reflects more CANO, that is, NO concentration in small airway. We observed that FENO\textsubscript{200} elevated in both stable and acute exacerbated COPD patients. Further subgroup analysis implied that FENO\textsubscript{200} in AECOPD patients with greater than 10ppb decreased after systemic corticosteroid therapy. However, no similar changes in CaNO were found. As we know, this is the first report of assessing the role of FeNO\textsubscript{200} in COPD and may have important clinical significance.

Figure 2 Changes in FeNO\textsubscript{50}, FeNO\textsubscript{200} and CaNO in different groups. FeNO\textsubscript{50} in patients with initial FeNO\textsubscript{50} > 25 ppb decreased after treatment (A). FeNO\textsubscript{50} in patients with initial FeNO\textsubscript{50} ≤ 25 ppb did not change after treatment (B). FeNO\textsubscript{200} in patients with initial FeNO\textsubscript{200} > 10 ppb decreased after treatment (C). FeNO\textsubscript{200} in patients with initial FeNO\textsubscript{200} ≤ 10 ppb did not change after treatment (D). CaNO in patients with initial CaNO > 5 ppb did not change after treatment (E). CaNO in patients with initial CaNO ≤ 5 ppb did not change after treatment (F).
We discovered that FeNO200 in COPD and AECOPD patients were higher than those in the healthy control group, reflecting the peripheral airway inflammation in COPD patients. Also, our research showed that FeNO200 was correlated with CRP in stable COPD patients, which was consistent with some findings in CaNO.15,16

Nevertheless, the same changes of CaNO were not found in this study. Our results are in line with a few studies, suggesting that CaNO did not differentiate healthy controls from COPD patients.18,27 However, several studies have found that the CaNO of COPD and AECOPD patients were higher than those of healthy controls.15,16 The inconsistency may be due to the use of different types of NO analyzers in these studies. CaNO varies with different flow rates, velocities, and various calculation models. Low, medium and high exhalation flow rates are needed for CaNO calculation, but this method is challenging to apply in COPD patients.11 Our pre-test showed that nitric oxide measurement only had a 70% success rate at 300 mL/s expiratory flow rate. Thus, FeNO200 can reflect peripheral airway inflammation more directly and accurately. Compared with the complex operation and calculation of CaNO, FeNO200 is an effective and simple method to evaluate small airway inflammation, especially in AECOPD patients. A larger sample size is needed for further research.

The peripheral airways NO measured by FeNO200 and the simplified CaNO were not elevated as we expected in AECOPD compared with the stable condition. Zsőfia Lázár also reported the same results in CaNO.16 The airway production of NO would change along with the expression of endothelial, neuronal, and inducible isoforms of NO synthase (eNOS, nNOS, and iNOS) in the peripheral lung tissue of COPD patients. iNOS is believed to play a critical role in the inflammatory response. iNOS is increased by inflammatory mediators and can generate tremendous amounts of NO.28 On the one hand, the activity of iNOS in AECOPD patients is enhanced by airway inflammation.29 On the other hand, hypoxia can induce damage to pulmonary capillaries endothelial cells and decrease eNOS activity.30 The NO concentration produced

### Table 4 The Difference from Baseline in FeNO200, CAT and Pulmonary Function Test

| Variables | High FeNO200 | Low FeNO200 | P-value |
|-----------|--------------|-------------|---------|
| FeNO200   | -24.0(-33.0,-2.0) | -1.50(-4.75,6.75) | 0.018 |
| CAT       | -6.00(-9.00,-4.00) | -2.50(-4.05,0.50) | 0.031 |
| FEV1/FVC  | 6.48(-0.74,8.68) | 2.44(-0.96,8.74) | 0.286 |
| FEV1% pred| 2.70(-0.90,16.70) | 6.35(-0.88,9.78) | 0.340 |
| FEV1      | 0.09(-0.05,0.28) | 0.17(-0.05,0.26) | 0.370 |
| PEF       | 0.20(-0.42,1.40) | 0.57(0.17,0.96) | 0.676 |
| PEF25     | 0.12(-0.15,0.72) | 0.18(0.00,0.48) | 0.906 |
| PEF50     | 0.12(-0.06,0.43) | 0.05(-0.02,0.23) | 0.427 |
| PEF75     | 0.06(0.01,0.18) | 0.03(-0.01,0.09) | 0.427 |

**Notes:** Data are presented as median (interquartile range); Kruskal–Wallis test for all other variables.

### Table 5 The Difference from Baseline in FeNO200, CAT and Pulmonary Function Test

| Variables | High FeNO200 | Low FeNO200 | P-value |
|-----------|--------------|-------------|---------|
| FeNO200   | -4.00(-6.00,1.00) | 0.50(-0.75,4.00) | 0.017 |
| CAT       | -4.00(-6.00,3.00) | 0.00(-3.75,0.50) | 0.031 |
| FEV1/FVC  | 2.62(-1.99,7.83) | 0.00(-0.17,13.76) | 0.542 |
| FEV1% pred| 3.50(-2.30,11.40) | 5.90(1.09,9.43) | 0.803 |
| FEV1      | 0.09(-0.04,0.24) | 0.19(-0.05,0.31) | 0.921 |
| PEF       | 0.72(-0.05,1.09) | 0.34(0.07,0.73) | 0.176 |
| PEF25     | 0.13(-0.10,0.50) | 0.32(0.09,0.71) | 0.611 |
| PEF50     | 0.05(-0.03,0.25) | 0.13(-0.02,0.28) | 0.863 |
| PEF75     | 0.02(-0.01,0.13) | 0.04(0.00,0.10) | 0.922 |

**Notes:** Data are presented as median (interquartile range); Kruskal–Wallis test for all other variables.

### Table 6 The Difference from Baseline in CaNO, CAT and Pulmonary Function Test

| Variables | High CaNO | Low CaNO | P-value |
|-----------|-----------|----------|---------|
| CaNO      | -1.50(-7.18,1.30) | 0.30(-1.30,4.05) | 0.107 |
| CAT       | -3.50(-5.00,5.00) | -3.00(-6.00,1.00) | 0.951 |
| FEV1/FVC  | 0.67(-1.81,4.47) | 6.48(0.22,14.42) | 0.135 |
| FEV1% pred| 3.50(-1.35,9.25) | 6.30(0.00,16.40) | 0.407 |
| FEV1      | 0.17(-0.07,0.27) | 0.09(-0.04,0.25) | 0.621 |
| PEF       | 0.67(0.11,1.02) | 0.34(-0.42,0.34) | 0.873 |
| PEF25     | 0.13(-0.13,0.40) | 0.20(-0.15,0.20) | 0.135 |
| PEF50     | 0.04(-0.06,0.09) | 0.25(-0.35,0.25) | 0.010 |
| PEF75     | -0.01(-0.01,0.08) | 0.04(-0.05,0.04) | 0.232 |

**Notes:** Data are presented as median (interquartile range); Kruskal–Wallis test for all other variables.
by eNOS decreased when it diffused from alveolar capillaries to alveoli. Therefore, influenced by multiple factors, the level of NO did not change significantly in AECOPD patients. Further research is needed to understand the mechanism better.

Our findings showed that FeNO\textsubscript{50} of AECOPD and stable COPD patients were higher than that of healthy controls, which agreed with previous studies. Zhiyu Lu reported that only a mild elevation of FeNO\textsubscript{50} levels patients with stable COPD.\textsuperscript{31} However, no significant difference was found in FeNO\textsubscript{50} between stable and exacerbated COPD patients. The reason may be consistent with FeNO\textsubscript{200} as described above, and large airway NO could be suppressed by ICS.\textsuperscript{31} Besides, the bacterial infection is an important cause of exacerbation of COPD. There was evidence showed that bacterial infection decreased FeNO\textsubscript{50} levels.\textsuperscript{32} NO levels at lower expiratory flow rates mainly indicate the bronchial inflammation; therefore, FeNO\textsubscript{50} cannot exactly reflect peripheral airway inflammation in COPD patients.

For AECOPD patients, there was no significant difference between FeNO\textsubscript{200} and CaNO after systemic corticosteroid treatment. This result may be attributed to the low initial exhaled NO values in some patients, and these patients had an inadequate response to corticosteroid treatment. By classifying patients based on the cut-off point of FeNO\textsubscript{50} > 25, We identified that 31% of patients with higher FeNO\textsubscript{50} levels had a significant FeNO\textsubscript{50} decrease and improved CAT after corticosteroid treatment, suggesting an excellent response to corticosteroid. This finding agreed with ATS’s guideline in 2011 that FeNO\textsubscript{50} greater than 25 ppb indicates eosinophilic inflammation and high FeNO\textsubscript{50} in COPD patients predict a good corticosteroid response.\textsuperscript{18,33}

Although there are no guidelines for FeNO\textsubscript{200} and CaNO, based on existing clinical studies, the FeNO\textsubscript{200} and CaNO values of healthy people are less than 10 ppb and 5 ppb, respectively.\textsuperscript{18,20,35-40} Our research showed a significant decrease in CAT and FeNO\textsubscript{200} in patients with FeNO\textsubscript{200} greater than 10 ppb after corticosteroid therapy. Patients with FeNO\textsubscript{200} below 10 ppb did not change after treatment, whereas CaNO did not change after 1 week’s corticosteroid treatment neither in the high CaNO value group nor in the low CaNO value group, which is similar to the previous study.\textsuperscript{16} The results implied that AECOPD patients with FeNO\textsubscript{200} > 10 ppb would benefit from corticosteroid.

GOLD recommended that COPD patients with circulating eosinophils >100 cells/µL can benefit from corticosteroid application. For patients with eosinophils <100 cells/µL, corticosteroid treatment is restrained due to poor response and the increased risk of pneumonia.\textsuperscript{41} In our study, 64% of patients had eosinophil counts greater than 100 cells/µL, similar to previous results.\textsuperscript{42} There were 59% AECOPD patients with FeNO\textsubscript{200} >10 ppb. However, only 31% of patients with AECOPD had FeNO\textsubscript{50} greater than 25 ppb. Therefore, FeNO\textsubscript{50} cannot truly reflect COPD’s inflammatory state, and only measuring FeNO\textsubscript{50} may miss some patients who would benefit from corticosteroid application. Compared with FeNO\textsubscript{50}, FeNO\textsubscript{200} may be a better indicator of corticosteroid therapy in COPD patients.

**Conclusion**

This study proved that FeNO\textsubscript{200} was a simpler and more patient-friendly method to directly measure the NO levels of peripheral airway/alveoli in COPD patients. In AECOPD patients with FeNO\textsubscript{200} > 10 ppb presented a better response.

---

**Figure 3** FeNO\textsubscript{200}, FeNO\textsubscript{500} and CaNO in healthy controls and COPD patients of different severity according to the classification of the Global Initiative for Chronic Obstructive Lung Disease (GOLD). FeNO\textsubscript{500} was not correlated with different GOLD stages (A). FeNO\textsubscript{200} was not correlated with GOLD stages (B). CaNO was elevated at stage of GOLD\textsuperscript{4} (C).
to corticosteroid treatment. Moreover, it is consistent with the guidance of peripheral blood eosinophils counts. Therefore, FeNO200 can be a type 2 inflammation biomarker and a useful tool for corticosteroid treatment in COPD.

Ethics Approval and Consent to Participate
The study was approved by the ethical review board of Wuxi People’s Hospital Affiliated to Nanjing Medical University. The ethics approval number was KS000024.

Acknowledgments
The study was supported by the project of the Jiangsu commission of Health [BJ15009 and BJ17009] and the Natural Science Foundation of Wuxi [JZYX01].

Disclosure
The authors declare that they have no conflicts of interest in this work.

References
1. Negewo NA, Gibson PG, McDonald VM. COPD and its comorbidities: impact, measurement and mechanisms. Respir Med. 2015;20:1160–1171. doi:10.1111/resp.12642
2. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138 (1):16–27. doi:10.1016/j.jaci.2016.05.011
3. Christenson SA, Steiling K, van den Berge M, et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(7):758–766. doi:10.1164/rccm.201408-1450OC
4. Oishi K, Matsunaga K, Shirai T, et al. Role of type2 inflammatory biomarkers in chronic obstructive pulmonary disease. J Clin Med. 2020;9(8):2670. doi:10.3390/jcm9082670
5. Beg MF, Alzoghaiby MA, Abba AA, et al. Exhaled nitric oxide in stable chronic obstructive pulmonary disease. Ann Thorac Med. 2009;4:65–70. doi:10.4103/1817-1737.44649
6. Bazeghi N, Gerds TA, Budtz-Jorgensen E, et al. Exhaled nitric oxide measure using multiple flows in clinically relevant subgroups of COPD. Respir Med. 2011;105:1338–1344. doi:10.1016/j.rmed.2011.03.015
7. Chou KT, Su KC, Huang SF, et al. Exhaled nitric oxide predicts eosinophilic airway inflammation in COPD. Lung. 2014;192:499–504. doi:10.1007/s00408-014-9591-8
8. Malerba M, Radaelli A, Olivini A, et al. Exhaled nitric oxide as a biomarker in COPD and related comorbidities. Biomed Res Int. 2014;2014:271918. doi:10.1155/2014/271918
9. Karampitsakos T, Gourgoulianis KI. Asthma-COPD overlap syndrome (ACOS): single disease entity or not? Could exhaled nitric oxide be a useful biomarker for the differentiation of ACOS, asthma and COPD? Med Hypotheses. 2016;91:20–23. doi:10.1016/j.mehy.2016.04.008
10. Alcazar-Navarrete B, Ruiz Rodriguez O, Conde Baena P, et al. Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. Eur Respir J. 2018;51:1701457. doi:10.1183/13993003.01457-2017
11. Horvath I, Barnes PJ, Loukides S, et al. A European respiratory society technical standard: exhaled biomarkers in lung disease. Eur Respir J. 2017;49:1600965. doi:10.1183/13993003.00965-2016
12. Hogman M, Holmkvist T, Wegener T, et al. Extended NO analysis applied to patients with COPD, allergic asthma and allergic rhinitis. Respir Med. 2002;96:24–30. doi:10.1053/rmed.2001.1204
13. Brindici C, Ito K, Rosta O, et al. Exhaled nitric oxide from lung periphery is increased in COPD. Eur Respir J. 2005;26:52–59. doi:10.1183/09031936.04.00125304
14. Williamson PA, Clearie K, Menzies D, et al. Assessment of small-airways disease using alveolar nitric oxide and impulse oximetry in asthma and COPD. Lung. 2011;189:121–129. doi:10.1007/s00408-010-9275-y
15. Hirano T, Matsunaga K, Sugihara H, et al. Relationship between alveolar nitric oxide concentration in exhaled air and small airway function in COPD. J Breath Res. 2013;7:046002. doi:10.1088/1752-7155/7/4/046002
16. Lazar Z, Kelemen A, Gallyf G, et al. Central and peripheral airway nitric oxide in patients with stable and exacerbated chronic obstructive pulmonary disease. J Breath Res. 2018;12:036017. doi:10.1088/1752-7163/aac10a
17. Short PM, Williamson PA, Lipworth BJ. Effects of extra-fine inhaled and oral corticosteroids on alveolar nitric oxide in COPD. Lung. 2012;190:395–401. doi:10.1007/s00408-012-9378-8
18. Gelb AF, Flynn Taylor C, Krishnan A, et al. Central and peripheral airway sites of nitric oxide gas exchange in COPD. Chest. 2010;137:575–584. doi:10.1378/chest.09-1522
19. Pareid P, Kharitonov SA, Meah S, et al. A novel approach to partition central and peripheral airway nitric oxide. Chest. 2014;145:113–119. doi:10.1378/chest.13-0843
20. Delcaux C, Mahut B, Zerah-Lancfer F, et al. Increased nitric oxide output from alveolar origin during liver cirrhosis versus bronchial source during asthma. Am J Respir Crit Care Med. 2002;165:332–337. doi:10.1164/ajrccm.165.3.2107017
21. Gupta S, Zamel N, Faughnan ME. Alveolar exhaled nitric oxide is elevated in hereditary hemorrhagic telangiectasia. Lung. 2009;187:43–49. doi:10.1007/s00408-008-9125-3
22. Lam Shin Cheung J, Naimi M, Sykes J, et al. A role for alveolar exhaled nitric oxide measurement in the diagnosis of hepatopulmonary syndrome. J Clin Gastroenterol. 2020;54:278–283. doi:10.1097/MCG.0000000000001246
23. American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171 (8):912–930. doi:10.1164/ajrccm.200406-710ST
24. Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol. 1998;85:653–666. doi:10.1152/jappl.1998.85.2.653
25. Hogman M, Merilainen P. Extended NO analysis in asthma. J Breath Res. 2007;1:024001. doi:10.1088/1752-7155/1/2/024001
26. Hogman M. Extended NO analysis in health and disease. J Breath Res. 2012;6:047103. doi:10.1088/1752-7155/6/4/047103
27. Lehouck A, Carremans C, De Bent K, et al. Alveolar and bronchial exhaled nitric oxide in cHR on obstrucctive pulmonary disease. Respir Med. 2010;104:1020–1026. doi:10.1016/j.rmed.2010.01.001
28. Sugihara H, Ichinose M. Nitritive stress in inflammatory lung diseases. Nitric Oxide. 2011;25:138–144. doi:10.1016/j.niox.2011.03.079
29. Pavord ID, Jones PW, Burgel PR, et al. Exacerbations of COPD, Int J Chron Obstruct Pulmon Dis. 2016;11:21–30. doi:10.2147/COPD.S85978
30. Zong F, Zuo XR, Wang Q, et al. Iptakalim rescues human pulmonary artery endothelial cells from hypoxia-induced nitric oxide system dysfunction. Exp Ther Med. 2012;3:535–539. doi:10.3892/etm.2011.414
31. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173:1114–1121. doi:10.1164/rccm.200506-859OC

32. Lu Z, Huang W, Wang L, et al. Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:2695–2705. doi:10.2147/COPD.S165780

33. Dweik TA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602–615. doi:10.1164/rccm.9120-11ST

34. Yamaji Y, Oishi K, Hamada K, et al. Detection of type2 biomarkers for response in COPD. J Breath Res. 2020;14:026007. doi:10.1088/1752-7163/ab71a4

35. Hogman M, Ludviksdottir D, Anderson SD, et al. Inhaled mannitol shifts exhaled nitric oxide in opposite directions in asthmatics and healthy subjects. Respir Physiol. 2001;124:141–150. doi:10.1016/S0034-5687(00)00195-X

36. Lehtimaki L, Kankaanranta H, Saarelainen S, et al. Extended exhaled NO measurement differentiates between alveolar and bronchial inflammation. Am J Respir Crit Care Med. 2001;163:1557–1561. doi:10.1164/ajrccm.163.7.2010171

37. Lehtimaki L, Kankaanranta H, Saarelainen S, et al. Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms. Eur Respir J. 2002;20:841–845. doi:10.1183/09031936.02.00202002

38. Tievä KM, Cabane J, Aubourg F, et al. Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide. Eur Respir J. 2007;30:26–30. doi:10.1183/09031936.00129806

39. Huo-Huy T, Tievä K, Chereau C, et al. Increased alveolar concentration of nitric oxide is related to serum-induced lung fibroblast proliferation in patients with systemic sclerosis. J Rheumatol. 2010;37:1680–1687. doi:10.3899/jrheum.090915

40. Wutte DM, Bozovic G, Hesselstrand R, et al. Increased alveolar nitric oxide in early systemic sclerosis. Clin Exp Rheumatol. 2010;28:S5–9.

41. Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53:1900164. doi:10.1183/13993003.00164-2019

42. Martinez-Garcia MA, Faner R, Oscullo G, et al. Inhaled steroids, circulating eosinophils, chronic airway infection, and pneumonia risk in chronic obstructive pulmonary disease: a network analysis. Am J Respir Crit Care Med. 2020;201:1078–1085. doi:10.1164/rccm.201908-1550OC